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Background. Chronic kidney disease (CKD) is a major so-
cial health problem because of the aging of the population, the
high incidence of diabetes mellitus, and the epidemic of silent
CKD resulting from inadequate diagnosis of early chronic renal
insufficiency
Methods. The sociodemographic, baseline characteristics and
CKD prevalence measured by the Modification of Diet in Re-
nal Disease formula were studied in a randomly selected sample
of people aged 20 years or older in the general population. We
report the results of the analysis of the EPIRCE (Estudio Epi-
demiolo´gico de la Insuficiencia Renal en Espan˜a) pilot study
performed in Galicia, Spain, in the last quarter of 2004.
Results. Baseline characteristics, sociodemographic charac-
teristics, and results of a clinical examination and blood vari-
ables were collected from 237 patients who fulfilled the study’s
inclusion and exclusion criteria. The mean age of the sample was
49.58 years (95% confidence interval, 47.39-51.76). The preva-
lence of Kidney Disease Outcomes Quality Initiative grade 3
CKD was 5.1%, but the coexistence of an albumin/creatinine
ratio >30 mg/g with grade 1 to 2 CKD raised the final rate to
12.7% in this population. We found a high prevalence of hy-
pertension (31.5%), isolated systolic hypertension (20.1%), di-
abetes mellitus (8%), obesity (13.1%), smoking habit (22.7%),
high atherogenic index (30.8%), and high alcohol intake (24%).
Risk factors significantly associated with renal disease were age
[P = 0.018; odds ratio (OR) 2.7], hypertension (P = 0.023; OR
2.13), pulse pressure (P = 0.04; OR 0.10), diabetes mellitus (P =
0.08; OR 4.48), obesity (P = 0.000; OR 7.7), and insulin resis-
tance index (P = 0.04; OR 4.95).
Conclusion. The prevalence of CKD and conventional car-
diovascular risk factors is high in this randomly selected sample
of the general population. Secondary preventive measures are
needed to detect chronic kidney impairment as early as possi-
ble and to reduce the incidence and mortality arising from the
associated comorbidities.
Chronic kidney disease (CKD) is a public health prob-
lem worldwide because of the increasing prevalence of
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type 2 diabetes mellitus and atherosclerosis-related re-
nal disease. This creates an important health care prob-
lem because a high proportion of these patients will need
renal replacement therapy. One of the barriers to early
detection of CKD is the lack of a precise, reliable, and
consistent measure of kidney function. In practice, the
glomerular filtration rate (GFR) is usually evaluated
with the serum plasma creatinine (SCr) concentration.
However, SCr concentration varies by age, sex, muscle
mass, and diet, and between laboratories. Moreover, SCr
concentration can remain within the normal range de-
spite significantly impaired renal function. The National
Health and Nutrition Examination Survey III (NHANES
III) study [1] reported that 11% of the United States pop-
ulation exhibits an abnormal SCr concentration, although
we do not know whether these data also apply to Spain
because such measurements are not always directly com-
parable [2–4].
In Spain, patients are referred to nephrology depart-
ments late in the course of the disease. The epidemiologic
data should be viewed with caution because the Modifica-
tion of Diet in Renal Disease (MDRD) equation under-
estimates GFR by 6.2% in patients with CKD and 29% in
healthy persons [5], and the method selected to estimate
renal function may affect the interpretation of the rela-
tion between cardiovascular risk factors and renal func-
tion. To study the relation between risk factors and renal
function in large population studies, indirect estimates of
renal function should be used with caution [6]. Never-
theless, the systematic evaluation of all patients and in-
corporation of simplified definitions should improve the
outcome in patients with kidney disease, and the MDRD
formula is a useful method for studying large populations.
Cardiovascular disease is the most common cause of
death in patients with CKD [7–9], who should be consid-
ered in the highest risk group for cardiovascular disease.
Traditional and nontraditional risk factors have been im-
plicated in the high prevalence of cardiovascular disease
associated with CKD. The inflammatory process starts
in the early phases of CKD, as shown by a GFR of 50 to
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60 mL/min [10], and accelerates vascular damage through
an increase in insulin resistance, stimulation of the ad-
hesion molecules, inhibition of nitric oxide synthesis,
endothelial dysfunction, and arteriosclerosis. The proin-
flammatory cytokines and impaired synthesis of erythro-
poietin are implicated in the onset of anemia, which
contributes significantly to the development of left ven-
tricular hypertrophy, a significant cause of mortality.
Well-established therapeutic interventions that delay or
prevent progressive kidney disease are incorporated
into the widely disseminated clinical practice guidelines,
which recommend aggressive treatment of traditional
and nontraditional risk factors. These interventions also
reduce the risk of cardiovascular disease and should be
regarded as essential components in the care of patients
with CKD.
For the reasons mentioned above, the Spanish
Nephrology Society is studying the prevalence of CKD in
Spain to provide useful information to identify the true
population at risk and to increase the preventive mea-
sures aimed at reducing the incidence of renal failure, car-
diovascular complications, and the progression to renal
sclerosis. This program is based on the concept that early
detection and prevention can influence the outcomes of
both renal insufficiency and cardiovascular morbidity and
mortality. This is the first study to investigate the preva-
lence of CKD in Spain. The Estudio Epidemiolo´gico de
la Insuficiencia Renal en Espan˜a (EPIRCE) study inves-
tigated GFR, calculated by a simplified MDRD formula,
in a randomly selected sample of the general population
20 years of age and older. We now report on the prelim-
inary data obtained from the pilot study performed in
Galicia, a region of Spain.
METHODS
The EPIRCE study is an epidemiologic, general
population-based, transversal study that includes a ran-
domly selected Spanish sample (N = 8400) aged 20 years
or older. The sample was stratified by age, sex, and region,
and is representative of all areas of Spain.
The initial sample results correspond to a pilot study
performed in Galicia, one of the areas selected initially to
identify potential difficulties before extending the study
to all areas of Spain.
This first pilot study included a randomly selected sam-
ple of 574 residents of Galicia. Of the original sample of
574, 63 were excluded from the study, 107 were not con-
tacted, and 165 refused to participate, leaving 239 who
met the inclusion criteria. The variables measured in-
cluded anthropometric data (weight, height, body mass
index) and baseline characteristics (obesity, history of
hypertension, diabetes mellitus, hypercholesterolemia,
hypertriglyceridemia). Participants were interviewed to
determine their smoking habits, alcohol consumption,
Table 1. Distribution of the sample size and the theoretical
assignment described in the protocol
Sample Planned population










and use of nephrotoxic drugs. After informed consent
was provided, a blood sample was obtained from each
individual for biochemical tests, which included serum
creatinine concentration determined in the same refer-
ence laboratory for all samples. GFR was calculated as
an indicator of renal function with the simplified MDRD
formula [11], and participants were classified according to
the Kidney Disease Outcomes Quality Initiative guide-
lines [12].
STATISTICAL METHODS
Quantitative variables were summarized in terms of
means and 95% confidence interval (CI); the compar-
ison between CKD groups was performed by using a
t test. Comparisons between categorical variables were
performed with chi-square test. Univariate and multivari-
ate logistic regression analyses were used to estimate the
odds ratio (OR) and CIs comparing vascular risk factors
on CKD occurrence. P < 0.05 was considered significant.
Analyses were performed with SPSS (Chicago, IL, USA).
RESULTS
The pilot study analyzed data for 237 participants or
41.6% of the initial sample of 574. This study sample
was distributed similarly to the estimated sample size de-
sign (Table 1). The mean age was 49.58 years (95% CI
47.39-51.76), and the prevalence of grade 3 CKD was
5% (Table 2). However, after the addition of partici-
pants classified as grade 1 or 2 CKD because they had
an albumin/creatinine ratio >30 mg/g, the prevalence of
CKD increased to 12.7%. The prevalence of associated
cardiovascular risk factors was high for arterial hyper-
tension (31.5%), isolated systolic hypertension (20.1%),
pulse pressure (27.8%), obesity (13.1%), diabetes mel-
litus (8%), a high atherogenic index (30.8%), hyper-
cholesterolemia (12.8%), hypertriglyceridemia (6.3%),
elevated low-density lipoprotein-cholesterol complex
(37.5%), low high-density lipoprotein-cholesterol com-
plex (18.1%), smoking >10 cigarettes/day (22.7%), and
high alcohol consumption >70 g/day (24%).
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Table 2. Prevalence of CKD according to the degree of renal
insufficiency and the pathologic albumin/creatinine index
Prevalence of CKD
Alb/Cr
GFR mL/min/1.73 m2 N Prevalence >30 mg/dL % Prevalence
>90 95 40.6 8 3.5
>60–89 127 54.3 8 3.5
>30–59 11 4.7 11 5.3
>15–29 1 0.4 1 0.4
<15 0 0 0 0
Total 234 100 28 12.5
Abbreviations are: CKD, chronic kidney disease; GFR, glomerular filtration
rate; Alb/Cr, albumin/creatinine.
Table 3. Prevalence (%) of conventional VRF according to the
stages of renal function (G1-G3)
VRF G1 G2 G3 P
HT 4.2 5.6 9.9 0.107
ISHT 5.9 5.9 14.7 0.038
PP 3.2 7.9 11.1 0.01
Obesity 4 4 8 0.471
DM 16.7 0 16.7 ND
Hypercholesterolemia 0 3.4 10.3 ND
Hypertriglyceridemia 0 20 6.7 ND
Low HDL-C concentration 4.8 4.8 9.5 0.505
High LDL-C concentration 3.6 2.4 4.4 0.880
AI 4.3 5.8 10.1 0.08
Abbreviations are: VRF, vascular risks factors; G1, GFR <90; G2, GFR
60–89; G3, GFR 30–59; HT, hypertension (blood pressure >140/90 mm Hg);
ISHT, isolated systolic HT (systolic blood pressure >140 and diastolic BP <90
mm Hg); PP, pulse pressure >60 mm Hg; obesity, BMI >29 kg/m2; DM, diabetes
mellitus (blood glucose concentration >126 mg/dL); hypercholesterolemia
>240 mg/dL; hypertriglyceridemia >200 mg/dL; low HDL-C concentration <35
mg/dL; high LDL-C concentration >160 mg/dL; AI, atherogenic index (>4);
ND, not determined.
The prevalence of cardiovascular risks factors in-
creased in proportion to GFR (Table 3). Univariate anal-
ysis identified the independent variables that correlated
significantly with GFR as age (OR 2.7), hypertension
(OR 2.13), pulse pressure (OR 0.101), diabetes mellitus
(OR 4.481), obesity (OR 7.7), and the insulin resistance
index (OR 4.95) (Table 4). However, GFR was corre-
lated significantly only with pulse pressure (P = 0.066;
OR 5.74) and diabetes mellitus (P = 0.060; OR 6.95) in
the multivariate analysis.
DISCUSSION
This preliminary report of a pilot study of 237 randomly
selected patients in Galicia is the first in a larger study of
the prevalence of CKD in the general population in Spain.
The larger study will include more than 8400 people and
aims to investigate the prevalence of silent CKD in the
Spanish population.
The approach to CKD and its management have
changed recently based on new epidemiologic, clinical,
and physiopathologic evidence showing that, even in its
early stages, CKD constitutes a significant risk factor for
Table 4. Risk of CKD and atherosclerotic risk factors. Univariate
logistic regression analysis.
Variable P OR 95% CI
Age 0.018 2.7 1.18, 6.31
HT 0.023 2.13 1.11, 4.11
ISHT 0.123 2.039 0.82, 5.04
PP 0.042 0.101 0.96, 3.90
DM 0.086 4.481 1.54, 13.04
Obesity 0.0000 7.7 2.65, 22.3
Hypercholesterolemia 0.11 2.08 0.84, 5.15
Hypertriglyceridemia 0.22 2.01 0.64, 6.29
High LDL-C concentration 0.230 1.437 0.77, 2.79
AI 0.70 1.845 0.95, 3.57
HOMA 0.04 4.95 1.07, 22.8
Smoking 0.26 0.73 0.43, 1.25
Alcohol 0.467 0.78 0.41, 1.50
Physical activity 0.92 1.03 0.50, 2.13
Abbreviations are: CKD, chronic kidney disease; OR, odds ratio; CI,
confidence interval; hypertension (blood pressure >140/90 mm Hg); ISHT,
isolated systolic hypertension (systolic blood pressure >140 and diastolic BP <90
mm Hg); PP, pulse pressure >60 mm Hg; DM, diabetes mellitus (blood glucose
concentration >126 mg/dL); obesity, BMI >29 kg/m2; hypercholesterolemia
>240 mg/dL; hypertriglyceridemia >200 mg/dL; high LDL-C concentration
>160 mg/dL; AI, atherogenic index (>4); HOMA, blood insulin × glucose
concentration/22.5; smoking >10 cigarettes/day; alcohol consumption >70 g/day.
cardiovascular and global morbidity and mortality be-
cause of the inflammatory state in the initial phases of
renal failure. For these reasons, the Seventh Report of
the Joint National Committee [13] includes microalbu-
minuria and a GFR <60 mL/min as significant cardiovas-
cular risk factors. The fundamental objective is to identify
people at risk of developing cardiovascular complications
among the apparently healthy and those already diag-
nosed with vascular disease or grade 1 or 2 CKD. Our
data from the EPIRCE pilot study are relevant because
of the high prevalence of conventional risk factors, CKD
(12.7%), and a GFR <60 mL/min (5.7%) in a population
with a mean age of 49.58 years. The overall prevalence of
CKD was 11% in the U.S.-based NHANES III study [1]
and 12.7% in our pilot study. The prevalence distribution
pattern using the National Kidney Foundation–Kidney
Disease Outcomes Quality Initiative stages of CKD was
3.3% in NHANES III and 3.5% in our study for stage 1,
3.0% in NHANES III and 3.5% in our study for stage 2,
4.3% in NHANES III and 5.3% in our study for stage 3,
0.25% in NHANES III and 0.4% in our study for stage
4, and 0.2% in NHANES III and 0% in our study for
stage 5 (end-stage renal failure); the latter value was very
low because of the small sample size. Others have re-
ported similar values. Anandarajah et al reviewed rou-
tinely collected data from 12 practices in 3 localities across
the United Kingdom and found that 4.9% of the regis-
tered population had an estimated GFR of <60 mL/min/
1.73 m2, which is equivalent to stages 3 to 5 CKD [14]. We
found a relatively high prevalence of asymptomatic CKD
in the apparently healthy general population in Spain.
We found that age, arterial hypertension, isolated
systolic hypertension, pulse pressure, diabetes mellitus,
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obesity, and the insulin resistance index were indepen-
dent variables related to renal disease. All of these vari-
ables reflect the combined effects of inflammation and
arteriosclerosis.
Prevention of CKD and its associated complications
needs a clear understanding of the prevalence and out-
come of renal disorders, the earlier stages of renal disease,
the risk factors, and the appropriate treatment of popu-
lations at risk. In the study by Anandarajah et al [14],
although 5% of the population had stages 3 to 5 CKD,
only a small proportion (8%) of these individuals had
received a renal diagnosis or had been seen by a renal
physician. Earlier identification of CKD in primary care,
better management of cardiovascular risk, the avoidance
of medication that impairs renal function, and specialist
referral where appropriate may improve long-term out-
comes. However, our understanding of this disease, its
risk factors, and its impact on the public health system is
incomplete, and no large epidemiologic studies have been
performed in Europe. Future studies should focus on the
prevalence and outcome of CKD and on the pathology
of the interaction between the kidney and cardiovascular
system to prevent the progression of renal dysfunction,
which should have a beneficial effect in reducing the risk
and prevalence of cardiovascular disease.
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